Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol adjunctive therapy in schizophrenia with inadequate antipsychotic response
2019-003369-16Phase 2Terminated
- Sponsor
- GW Pharmaceuticals
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Cannabidiol adjunctive therapy with Placebo adjunctive therapy (2 arms). Started Mar 2020; status: terminated.
02
Drugs
cannabidiol
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2019-003369-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003369-16.